Primary immunodeficiencies with predominant impairment of antibody synthesis

The urgency of the problem of primary immunodeficiencies (PID) lies in the late diagnosis of this pathology due to the low awareness of doctors of various specialties, the formation of chronic diseases in patients, and high mortality in this group of patients. Currently, the concept of PID includes both traditional concepts - defects leading to the development of quantitative and / or functional insufficiency, and new concepts - uncontrolled activation of the proliferation of immunocompetent cells and the formation of autoimmune, auto-inflammatory and allergic diseases. The article discusses the diagnostic criteria for PID and the main directions in the treatment of this contingent of patients

Impact of Host Immune Status on Discordant Anti-SARS-CoV-2 Circulating B Cell Frequencies and Antibody Levels

Individuals with pre-existing chronic systemic low-grade inflammation are prone to develop severe COVID-19 and stronger anti-SARS-CoV-2 antibody responses. Whether this phenomenon reflects a differential expansion of antiviral B cells or a failure to regulate antibody synthesis remains unknown. Here, we compared the antiviral B cell repertoire of convalescent healthcare personnel to that of hospitalized patients with pre-existing comorbidities. Out of 277,500 immortalized B cell clones, antiviral B cell frequencies were determined by indirect immunofluorescence screening on SARS-CoV-2 infected cells. Surprisingly, frequencies of SARS-CoV-2 specific clones from the two groups were not statistically different, despite higher antibody levels in hospitalized patients. Moreover, functional analyses revealed that several B cell clones from healthcare personnel with low antibody levels had neutralizing properties. This study reveals for the first time a key qualitative defect of antibody synthesis in severe patients and calls for caution regarding estimated protective immunity based only on circulating antiviral antibodies.

The Role of B Cells in Primary Progressive Multiple Sclerosis

The success of ocrelizumab in reducing confirmed disability accumulation in primary progressive multiple sclerosis (PPMS) via CD20-targeted depletion implicates B cells as causal agents in the pathogenesis of PPMS. This review explores the possible mechanisms by which B cells contribute to disease progression in PPMS, specifically exploring cytokine production, antigen presentation, and antibody synthesis. B cells may contribute to disease progression in PPMS through cytokine production, specifically GM-CSF and IL-6, which can drive naïve T-cell differentiation into pro-inflammatory Th1/Th17 cells. B cell production of the cytokine LT-α may induce follicular dendritic cell production of CXCL13 and lead indirectly to T and B cell infiltration into the CNS. In contrast, production of IL-10 by B cells likely induces an anti-inflammatory effect that may play a role in reducing neuroinflammation in PPMS. Therefore, reduced production of IL-10 may contribute to disease worsening. B cells are also capable of potent antigen presentation and may induce pro-inflammatory T-cell differentiation via cognate interactions. B cells may also contribute to disease activity via antibody synthesis, although it's unlikely the benefit of ocrelizumab in PPMS occurs via antibody decrement. Finally, various B cell subsets likely promulgate pro- or anti-inflammatory effects in MS.

The condition of piglet immune system during post-weaning period depending on the sex and stress-reactivity

The immune system of 90-day old piglets of SM-1 Novosibirsk breed piglets depends on sex and stress-reactivity. Stress-reactivity was measured using halothane test. The immunologic testing was performed 30 days after weaning. Our results show that overall piglet immune system demonstrated high proliferative activity of T- and B- immunocompetent cells with active formation of mature active T-and B-lymphocytes and did not show signs of immunosuppression. Compared to guilts, barrows had higher concentration of leucocytes, T-and B-lymphocytes, killer-supressor T-cells, activated and poorly differentiated T-lymphocytes. Gilts had higher production of inductor-helper T-cells, IgM and IgG when compared to barrows. Stress-resistant piglets had higher concentration of B-lymphocytes, IgM and IgG whereas stress-sensitive piglets had higher concentration of T-lymphocytes, supressor-killer T-cells and thymus T-lymphocytes. Gilts had higher concentration of inductor-helper T-cells than killer-supressor T-cells. Gilts overall had intensive antibody synthesis, however, stress-resistant gilts had higher IgG synthesis compared to stress-sensitive gilts. In barrows immature T-lymphocytes differentiated mainly into killer-supressor T-cells. The adaptivity of barrow immune system was characterized by high circulatory B-lymphocytes and IgM. Stress-sensitive barrows had lower antibody synthesis levels and higher T-lymphophoesis compared to stress-resistant barrows.

EFFECT OF PHYLLANTHUS NIRURI L. EXTRACT AS IMMUNOSTIMULATOR ON CHICKEN VACCINATED BY NEWCASTLE DISEASE

Newcastle Disease or tetelo is one of main problem in poultry Industry in Indonesia. Prevention such as biosecurity control and routin vaccination program have been conducted to overcome this problem, but they have not given any great impact. Phyllanthus Niruri L. or meniran is well known as immunostimulatory. This research was aimed to reveal effect of Phyllanthus Niruri L. extract on chicken vaccinated with live vaccine LaSota. Administration of Phyllanthus Niruri L. extract was conducted on three different time which were 7 days before vaccination, 1 days after vaccination, and 3 days before and after vaccination. The amount of Phyllanthus Niruri L. extract administered were 2 ml, 2.5 ml, and 3 ml orally. Data of antibody titre were collected for 4 weeks after the treatment. It was obtained by measuring the antibody through Haemagglutination Inhibition test each week. According to the result Phyllanthus Niruri L. extract could increase the amount of antibody titre against Newcastle Disease. The amount of Phyllanthus Niruri L. extract given that capable to induced maximum of antibody titre was administered 1 days after the vaccination with amount 2.5 ml. It is suggested that Phyllanthus Niruri L. extract should be administered post vaccination to boost antibody synthesis.

STATE OF HUMORAL DEFENSE MECHANISMS IN PIGLETS OF DIF-FERENT AGE GROUPS UNDER NON-SPECIFIC BRONCHOPNEUMONIA

Respiratory diseases in pigs are wide-spread. They cause great economic damage to farms, it is summed up both from the cull-ing and death of animals in different age periods, and from a decrease in weight gain against the background of chronic hypoxia. The incidence of non-specific bronchopneu-monia in pigs in some farms can reach 80%. Violation of zoohygienic conditions of de-tention contributes to morbidity. The aim of the study was to study the state of some indicators of the innate and adaptive immune response in non - specific pneumonia in sick piglets and healthy piglets of different age groups-suckling piglets, pig-lets of rearing and fattening groups kept in a large pig complex. As a result of research, it was found that all piglets with bronchopneumonia have a violation of the protective mechanisms of the innate and adaptive immune links. During all periods of the study, impaired antibody synthesis was observed. The humoral mechanisms of innate im-munity were significantly weakened. In our opinion, it is the defect of humoral innate mechanisms that can contribute to the occur-rence and maintenance of the inflammatory process in the lungs.

ОЦЕНКА ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ 10% ВНУТРИВЕННОГО ИММУНОГЛОБУЛИНА ПРИВИДЖЕН В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ

Актуальность. Заместительная терапия иммуноглобулинами человека является ведущим патогенетическим методом лечения первичных иммунодефицитов с нарушением синтеза антител. В настоящее время в России доступно несколько препаратов иммуноглобулинов человека нормальных для внутривенного введения. Цель. Оценить эффективность и безопасность препарата Привиджен (10 раствор иммуноглобулина для внутривенного введения) в реальной клинической практике в течение 12 клинических месяцев. Материалы и методы. 20 взрослых с диагнозом общая вариабельная иммунная недостаточности и Х-сцепленная агаммаглобулинемия получали внутривенный иммуноглобулин Привиджен к интервалом 243 дня в течение 12 мес. Первичными критериями оценки была частота инфекционных осложнений и нежелательных явлений. Результаты. У большинства пациентов в ходе исследования достигнут удовлетворительный претранс-фузионный уровень IgG. Тяжелых нежелательных явлений, связанных с введением препарата, не зарегистрировано. Заключение. В ходе исследования препарат продемонстрировал высокую эффективность и безопасность у пациентов, нуждающихся в ежемесячной заместительной терапииRelevance. Replacement therapy with human immunoglobulins is the leading pathogenetic method of treatment of primary immunodeficiency with impaired antibody synthesis. Currently, several preparations of human immunoglobulins for intravenous administration are available in Russia. Purposes. Evaluation of the efficacy and safety of Privigen immunoglobulin intravenous 10 liquid in real clinical practice within 12 clinical months. Methods. Twenty adults diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen infusions (0.2-0.4 mg/kg) at 243 intervals over a 12-month period. The primary endpoint was the annual rate of infections and adverse events. Results. Sufficient level of IgG was achieved in most patients during the study. Severe adverse reactions during the treatment were not registered. Conclusions. High efficacy and safety of monthly replacement therapy in patients with primary immunodeficiency with impaired antibody synthesis has been demonstrated.